Reportlinker Adds Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market

News provided by

Reportlinker

14 Apr, 2011, 06:44 ET

NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market

http://www.reportlinker.com/p0481589/Sleep-Disorders-Market-to-2017---Generic-Substitution-Coupled-With-a-Weak-Pipeline-Will-Negatively-Impact-the-Market.html

Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Sleep Disorders Market to 2017- Generics Substitution Coupled with a Weak Pipeline Will Negatively Impact the Market", which provides insights into sleep disorders therapeutics sales and price forecasts until 2017. The report also examines the global sleep disorders treatment usage patterns. In addition, the geographical distribution of sleep disorders therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the sleep disorders R&D pipeline. The report provides an in-depth analysis of the top four sleep disorders therapeutic indications, which are insomnia, restless leg syndrome, narcolepsy and sleep apnea. Furthermore, it also includes the market forecasts and treatment usage patterns of these four therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving sleep disorders treatments is also presented.

Scope

The report covers -

- Data and analysis on the sleep disorders therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Annualized market data for the sleep disorders therapeutics market from 2002 to 2010, with forecasts to 2017.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- Key drivers and restraints that have had a significant impact on the market.

- The competitive landscape of the global sleep disorders therapeutics market including top companies benchmarking. The key companies studied in this report are Sanofi-aventis, King pharmaceuticals, questcor pharmaceuticals, Novartis, GlaxoSmithKline, plc, Pfizer and Boehringer Ingelheim

- Key M&A activities and Licensing Agreements that took place in 2008 and 2010 in the sleep disorders therapeutics market.

Reasons to buy

The report will assist business development and marketing executives to strategize their product launches, by allowing them to -

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 9

2 Sleep Disorders Market: Introduction 11

2.1 GBI Research Report Guidance 12

3 Sleep Disorders Market to 2017: Market Overview 13

3.1 Introduction 13

3.2 Revenue Forecasts for the Sleep Disorder Therapeutics Market 14

3.2.1 Revenue 14

3.2.2 Annual Cost of Treatment (ACT) 15

3.2.3 Treatment Usage Patterns 17

4 Sleep Disorders Market to 2017: Geographical Landscape 23

4.1 Revenue Analysis by Geography 23

4.2 The US 25

4.2.1 Revenue 25

4.2.2 Annual Cost of Treatment 26

4.2.3 Treatment Usage Patterns 28

4.3 Top Five Countries of Europe 35

4.3.1 Revenue 35

4.3.2 Annual Cost of Treatment 36

4.3.3 Treatment Usage Patterns 37

4.4 Japan 43

4.4.1 Revenue 43

4.4.2 Annual Cost of Treatment 44

4.4.3 Treatment Usage Patterns 45

5 Sleep Disorders Market: Therapeutic Landscape 51

5.1 Insomnia Therapeutics Market 51

5.1.1 Introduction 51

5.1.2 Revenue 52

5.1.3 Annual Cost of Treatment 53

5.1.4 Treatment Usage Patterns 54

5.1.5 Drivers and Barriers for the Insomnia Therapeutics Market 60

5.2 Restless Leg Syndrome Therapeutics Market 61

5.2.1 Introduction 61

5.2.2 Revenue 62

5.2.3 Annual Cost of Treatment 63

5.2.4 Treatment Usage Patterns 64

5.2.5 Drivers and Barriers for the Restless Leg Syndrome Therapeutics Market 70

5.3 Narcolepsy Therapeutics Market 71

5.3.1 Introduction 71

5.3.2 Revenue 72

5.3.3 Annual Cost of Treatment 73

5.3.4 Treatment Usage Patterns 74

5.3.5 Drivers and Barriers for the Narcolepsy Therapeutics Market 80

5.4 Sleep Apnea Therapeutics Market 81

5.4.1 Introduction 81

5.4.2 Revenue 82

5.4.3 Annual Cost of Treatment 83

5.4.4 Treatment Usage Patterns 84

5.4.5 Drivers and Barriers for the Sleep Apnea Therapeutics Market 90

6 Sleep Disorders Market to 2017: Pipeline Analysis 92

6.1 Introduction 92

6.2 Research and Development Pipeline – Sleep Disorders 93

6.3 Insomnia – Pipeline Analysis 93

6.3.1 Introduction 93

6.3.2 Insomnia Therapeutics Market – Pipeline Assessment by Clinical Phase of Development 94

6.3.3 Filed Molecules 95

6.3.4 Phase III 95

6.3.5 Phase II 96

6.3.6 Phase I 97

6.3.7 Preclinical Phase 97

6.3.8 Discovery Phase 97

6.4 Restless Leg Syndrome Therapeutics Market: Pipeline Analysis 98

6.4.1 Introduction 98

6.4.2 Narcolepsy Therapeutics Market – Pipeline Assessment by Clinical Phase of Development 99

6.5 Narcolepsy Therapeutics Market – Pipeline Analysis 100

6.5.1 Introduction 100

6.5.2 Narcolepsy Therapeutics Market – Pipeline Assessment by Clinical Phase of Development 101

6.6 Sleep Apnea Therapeutics Market – Pipeline Analysis 102

6.6.1 Introduction 102

6.6.2 Sleep Apnea Therapeutics Market – Pipeline Assessment by Clinical Phase of Development 103

7 Sleep Disorder Market to 2016: Competitive Landscape 104

7.1 Overview 104

7.2 Competitive Profiling 104

7.2.1 Sanofi-Aventis 104

7.2.2 King Pharmaceuticals, Inc. 107

7.2.3 Questcor Pharmaceuticals, Inc. 108

7.2.4 Novartis 109

7.2.5 GlaxoSmithKline plc 111

7.2.6 Pfizer 113

7.2.7 Boehringer Ingelheim 115

7.2.8 Cephalon Pharmaceuticals 119

7.2.9 Schwarz Pharma 121

7.2.10 Mylan Pharma 125

8 Sleep Disorders Market to 2017: M&A Landscape 127

8.1 Sleep Disorders Market 127

8.1.1 Overview: Deals by Type 127

8.1.2 Deals by Year 128

8.2 Mergers and Acquisitions 128

8.2.1 Overview 128

8.2.2 Meda Acquires Commercialization Rights of Sublinox and OX-NLA from Orexo 128

8.2.3 Eli Lilly Acquires Hypnion 129

8.2.4 Endo Pharmaceuticals Completes Acquisition of Penwest Pharmaceutical 129

8.2.5 Sciele Pharma Acquires Alliant Pharmaceuticals 130

8.2.6 Jazz Pharmaceuticals Acquires Orphan Medical 130

8.2.7 Paul Royalty Acquires US Royalty Rights of Estorra from Aventis 130

8.3 Licensing Agreements 132

8.3.1 GlaxoSmithKline (GSK) and Actelion Pharmaceuticals 132

8.3.2 Purdue Pharma Enters into License Agreement with Transcept Pharmaceuticals 132

8.3.3 Neurocrine Biosciences Enters into Licensing Agreement with Dainippon Sumitomo Pharma 133

8.3.4 Eli Lilly Enters into Licensing Agreement with Merck 133

8.3.5 ECR Pharmaceuticals Enters into License Agreement with NovaDel Pharma 133

8.3.6 Vanda Enters into Licensing Agreement with Bristol-Myers Squibb 134

8.4 Co-Development Strategies 135

9 Sleep Disorders Market: Appendix 136

9.1 Market Definition 136

9.2 Abbreviations 136

9.3 Research Methodology 137

9.3.1 Coverage 137

9.3.2 Secondary Research 137

9.3.3 Forecasting 138

9.3.4 Primary Research 140

9.3.5 Expert Panels 140

9.4 Contact Us 140

9.5 Disclaimer 141

9.6 Sources 141

1.1 List of Tables

Table 1: Sleep Disorders Market, Global, Revenue ($bn), 2002-2010 14

Table 2: Sleep Disorders Market, Global, Revenue Forecasts ($bn), 2010-2017 14

Table 3: Sleep Disorders Market, Global, Annual Cost of Treatment ($), 2002-2010 16

Table 4: Sleep Disorders Market, Global, Annual Cost of Treatment ($), 2010-2017 16

Table 5: Sleep Disorders Market, Global, Treatment Usage Patterns (millions), 2002-2010 17

Table 6: Sleep Disorders Market, Global, Treatment Usage Patterns (millions), 2010-2017 18

Table 7: Sleep Disorders Market, Global, Diseased Population (millions), 2002–2010 19

Table 8: Sleep Disorders Market, Global, Diseased Population (millions), 2010–2017 19

Table 9: Sleep Disorders Market, Global, Treatment Seeking Population (millions), 2002–2010 20

Table 10: Sleep Disorders Market, Global, Treatment Seeking Population (millions), 2010–2017 20

Table 11: Sleep Disorders Market, Global, Diagnosed Population (million), 2002–2010 21

Table 12: Sleep Disorders Market, Global, Diagnosed Population (million), 2010–2017 21

Table 13: Sleep Disorders Market, Global, Prescription Population (million), 2002–2010 22

Table 14: Sleep Disorders Market, Global, Prescription Population (million), 2010–2017 22

Table 15: Sleep Disorders Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 24

Table 16: Sleep Disorders Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 24

Table 17: Sleep Disorders Market, the US, Revenue ($bn), 2002-2010 25

Table 18: Sleep Disorders Market, the US, Revenue Forecasts ($bn), 2010-2017 25

Table 19: Sleep Disorders Market, the US, Annual Cost of Treatment ($), 2002-2010 27

Table 20: Sleep Disorders Market, the US, Annual Cost of Treatment ($), 2010-2017 27

Table 21: Sleep Disorders Market, the US, Treatment Usage Patterns (millions), 2002-2010 28

Table 22: Sleep Disorders Market, the US, Treatment Usage Patterns (millions), 2010-2017 29

Table 23: Sleep Disorders Market, the US, Diseased Population (millions), 2002–2010 30

Table 24: Sleep Disorders Market, the US, Diseased Population (millions), 2010–2017 30

Table 25: Sleep Disorders Market, the US, Treatment Seeking Population (millions), 2002–2010 32

Table 26: Sleep Disorders Market, the US, Treatment Seeking Population (millions), 2010–2017 32

Table 27: Sleep Disorders Market, the US, Diagnosed Population (millions), 2002–2010 33

Table 28: Sleep Disorders Market, the US, Diagnosed Population (millions), 2010–2017 33

Table 29: Sleep Disorders Market, the US, Prescription Population (millions), 2002–2010 34

Table 30: Sleep Disorders Market, the US, Prescription Population (millions), 2010–2017 34

Table 31: Sleep Disorders Market, Top Five EU Countries, Revenue ($bn), 2002-2010 35

Table 32: Sleep Disorders Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2017 35

Table 33: Sleep Disorders Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2002-2010 36

Table 34: Sleep Disorders Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2010-2017 36

Table 35: Sleep Disorders Market, Top Five Countries in the EU, Treatment Usage Patterns (millions), 2002-2010 37

Table 36: Sleep Disorders Market, Top Five Countries in the EU, Treatment Usage Patterns (millions), 2010-2017 38

Table 37: Sleep Disorders Market, Top Five Countries in Europe, Diseased Population (millions), 2002–2010 39

Table 38: Sleep Disorders Market, Top Five Countries in Europe, Diseased Population (millions), 2010–2017 39

Table 39: Sleep Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (millions), 2002–2010 40

Table 40: Sleep Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (millions), 2010–2017 40

Table 41: Sleep Disorders Market, Top Five Countries in Europe, Diagnosed Population (millions), 2002–2010 41

Table 42: Sleep Disorders Market, Top Five Countries in Europe, Diagnosed Population (millions), 2010–2017 41

Table 43: Sleep Disorders Market, Top Five Countries in Europe, Prescription Population (millions), 2002–2010 42

Table 44: Sleep Disorders Market, Top Five Countries in Europe, Prescription Population (millions), 2010–2017 42

Table 45: Sleep Disorders Market, Japan, Revenue ($bn), 2002-2010 43

Table 46: Sleep Disorders Market, Japan, Revenue Forecast ($bn), 2010-2017 43

Table 47: Sleep Disorders Market, Japan, Annual Cost of Treatment ($), 2002-2010 44

Table 48: Sleep Disorders Market, Japan, Annual Cost of Treatment ($), 2010-2017 44

Table 49: Sleep Disorders Market, Japan, Treatment Usage Patterns (millions), 2002-2010 45

Table 50: Sleep Disorders Market, Japan, Treatment Usage Patterns (millions), 2010-2017 46

Table 51: Sleep Disorders Market, Japan, Diseased Population (millions), 2002–2010 47

Table 52: Sleep Disorders Market, Japan, Diseased Population (millions), 2010–2017 47

Table 53: Sleep Disorders Market, Japan, Treatment Seeking Population (millions), 2002–2010 48

Table 54: Sleep Disorders Market, Japan, Treatment Seeking Population (millions), 2010–2017 48

Table 55: Sleep Disorders Market, Japan, Diagnosed Population (millions), 2002–2010 49

Table 56: Sleep Disorders Market, Japan, Diagnosed Population (millions), 2010–2017 49

Table 57: Sleep Disorders Market, Japan, Prescription Population (millions), 2002–2010 50

Table 58: Sleep Disorders Market, Japan, Prescription Population (millions), 2010–2017 50

Table 59: Insomnia Therapeutics Market, Global, Revenue ($bn), 2002-2010 52

Table 60: Insomnia Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 52

Table 61: Insomnia Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 53

Table 62: Insomnia Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 53

Table 63: Insomnia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 54

Table 64: Insomnia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017 55

Table 65: Insomnia Therapeutics Market, Global, Diseased Population (millions), 2002-2010 56

Table 66: Insomnia Therapeutics Market, Global, Diseased Population (millions), 2010-2017 56

Table 67: Insomnia Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2010 57

Table 68: Insomnia Therapeutics Market, Global, Treatment Seeking Population (millions), 2010-2017 57

Table 69: Insomnia Therapeutics Market, Global, Diagnosed Population (millions), 2002-2010 58

Table 70: Insomnia Therapeutics Market, Global, Diagnosed Population (millions), 2010-2017 58

Table 71: Insomnia Therapeutics Market, Global, Prescription Population (millions), 2002-2010 59

Table 72: Insomnia Therapeutics Market, Global, Prescription Population (millions), 2010-2017 59

Table 73: Restless Leg Syndrome Therapeutics Market, Global, Revenue ($bn), 2002-2010 62

Table 74: Restless Leg Syndrome Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 62

Table 75: Restless Leg Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 63

Table 76: Restless Leg Syndrome Therapeutics Market, Global, Annual Cost of Treatment($), 2010-2017 63

Table 77: Restless Leg Syndrome Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 64

Table 78: Restless Leg Syndrome Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017 65

Table 79: Restless Leg Syndrome Therapeutics Market, Global, Diseased Population (millions), 2002-2010 66

Table 80: Restless Leg Syndrome Therapeutics Market, Global, Diseased Population (millions), 2010-2017 66

Table 81: Restless Leg Syndrome Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2010 67

Table 82: Restless Leg Syndrome Therapeutics Market, Global, Treatment Seeking Population (millions), 2010-2017 67

Table 83: Restless Leg Syndrome Therapeutics Market, Global, Diagnosed Population (millions), 2002-2010 68

Table 84: Restless Leg Syndrome Therapeutics Market, Global, Diagnosed Population (millions), 2010-2017 68

Table 85: Restless Leg Syndrome Therapeutics Market, Global, Prescription Population (millions), 2002-2010 69

Table 86: Restless Leg Syndrome Therapeutics Market, Global, Prescription Population (millions), 2010-2017 69

Table 87: Narcolepsy Therapeutics Market, Global, Revenue ($m), 2002-2010 72

Table 88: Narcolepsy Therapeutics Market, Global, Revenue Forecast ($m), 2010-2017 72

Table 89: Narcolepsy Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 73

Table 90: Narcolepsy Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 73

Table 91: Narcolepsy Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2010 74

Table 92: Narcolepsy Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2010-2017 75

Table 93: Narcolepsy Therapeutics Market, Global, Diseased Population (thousands), 2002-2010 76

Table 94: Narcolepsy Therapeutics Market, Global, Diseased Population (thousands), 2010-2017 76

Table 95: Narcolepsy Therapeutics Market, Global, Treatment Seeking Population (thousands), 2002-2010 77

Table 96: Narcolepsy Therapeutics Market, Global, Treatment Seeking Population (thousands), 2010-2017 77

Table 97: Narcolepsy Therapeutics Market, Global, Diagnosed Population (thousands), 2002-2010 78

Table 98: Narcolepsy Therapeutics Market, Global, Diagnosed Population (thousands), 2010-2017 78

Table 99: Narcolepsy Therapeutics Market, Global, Prescription Population (thousands), 2002-2010 79

Table 100: Narcolepsy Therapeutics Market, Global, Prescription Population (thousands), 2010-2017 79

Table 101: Sleep Apnea Therapeutics Market, Global, Revenue ($m), 2002-2010 82

Table 102: Sleep Apnea Therapeutics Market, Global, Revenue Forecast ($m), 2010-2017 82

Table 103: Sleep Apnea Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 83

Table 104: Sleep Apnea Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 83

Table 105: Sleep Apnea Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 84

Table 106: Sleep Apnea Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017 85

Table 107: Sleep Apnea Therapeutics Market, Global, Prescription Population (millions), 2002-2010 86

Table 108: Sleep Apnea Therapeutics Market, Global, Diseased Population (millions), 2010-2017 86

Table 109: Sleep Apnea Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2010 87

Table 110: Sleep Apnea Therapeutics Market, Global, Treatment Seeking Population (millions), 2010-2017 87

Table 111: Sleep Apnea Therapeutics Market, Global, Diagnosed Population (millions), 2002-2010 88

Table 112: Sleep Apnea Therapeutics Market, Global, Diagnosed Population (millions), 2010-2017 88

Table 113: Sleep Apnea Therapeutics Market, Global, Prescription Population (millions), 2002-2010 89

Table 114: Sleep Apnea Therapeutics Market, Global, Prescription Population (millions), 2010-2017 89

Table 115: Insomnia Therapeutics Market, Global, Pipeline Analysis, NDA Filed Molecules 95

Table 116: Insomnia Therapeutics Market, Global, Pipeline Analysis, Phase III 95

Table 117: Insomnia Therapeutics Market, Global, Pipeline Analysis, Phase II 96

Table 118: Insomnia Therapeutics Market, Global, Pipeline Analysis, Phase I 97

Table 119: Insomnia Therapeutics Market, Global, Pipeline Analysis, Preclinical Phase 97

Table 120: Insomnia Therapeutics Market, Global, Pipeline Analysis, Discovery Phase 97

Table 121: Restless Leg Syndrome Therapeutics Market, Global, Pipeline Analysis 99

Table 122: Narcolepsy Therapeutics Market, Global, Pipeline Analysis 101

Table 123: Restless Leg Syndrome Therapeutics Market, Global, Pipeline Analysis 103

Table 124: Sleep Disorders Market, Global, Major M&A Deals, 2004-2010 131

1.2 List of Figures

Figure 1: Sleep Disorders Market, Global, Revenue Forecasts ($bn), 2002-2017 14

Figure 2: Sleep Disorders Market, Annual Cost of Treatment ($), 2002-2017 15

Figure 3: Sleep Disorders Market, Global, Treatment Usage Patterns (millions), 2002-2017 17

Figure 4: Sleep Disorders Market, Global, Diseased Population (millions), 2002-2017 19

Figure 5: Sleep Disorders Market, Global, Treatment Seeking Population (millions), 2002-2017 20

Figure 6: Sleep Disorders Market, Global, Diagnosis Population (million), 2002-2017 21

Figure 7: Sleep Disorders Market, Global, Prescription Population (million), 2002-2017 22

Figure 8: Sleep Disorders Market, Global, Revenue Analysis by Geography ($m), 2002-2017 23

Figure 9: Sleep Disorders Market, the US, Revenue Forecasts ($bn), 2002-2017 25

Figure 10: Sleep Disorders Market, the US, Annual Cost of Treatment ($), 2002-2017 26

Figure 11: Sleep Disorders Market, the US, Treatment Usage Patterns (millions), 2002-2017 28

Figure 12: Sleep Disorders Market, the US, Diseased Population (millions), 2002-2017 30

Figure 13: Sleep Disorders Market, the US, Treatment Seeking Population (millions), 2002-2017 31

Figure 14: Sleep Disorders Market, the US, Diagnosis Population (millions), 2002-2017 33

Figure 15: Sleep Disorders Market, the US, Prescription Population (millions), 2002-2017 34

Figure 16: Sleep Disorders Market, Top Five EU Countries, Revenue Forecasts ($bn), 2002-2017 35

Figure 17: Sleep Disorders Market, Top Five Countries in the EU, Annual Cost of Treatment ($), 2002-2017 36

Figure 18: Sleep Disorders Market, Top Five Countries in the EU, Treatment Usage Patterns (millions), 2002-2017 37

Figure 19: Sleep Disorders Market, Top Five Countries in the EU, Diseased Population (millions), 2002-2017 39

Figure 20: Sleep Disorders Market, Top Five Countries in the EU, Treatment Seeking Population (millions), 2002-2017 40

Figure 21: Sleep Disorders Market, Top Five Countries in the EU, Diagnosis Population (millions), 2002-2017 41

Figure 22: Sleep Disorders Market, Top Five Countries in the EU, Prescription Population (millions), 2002-2017 42

Figure 23: Sleep Disorders Market, Japan, Revenue Forecast ($bn), 2002-2017 43

Figure 24: Sleep Disorders Market, Japan, Annual Cost of Treatment ($), 2002-2017 44

Figure 25: Sleep Disorders Market, Japan, Treatment Usage Patterns (millions), 2002-2017 45

Figure 26: Sleep Disorders Market, Japan, Diseased Population (millions), 2002-2017 47

Figure 27: Sleep Disorders Market, Japan, Treatment Seeking Population (millions), 2002-2017 48

Figure 28: Sleep Disorders Market, Japan, Diagnosis Population (millions), 2002-2017 49

Figure 29: Sleep Disorders Market, Japan, Prescription Population (millions), 2002-2017 50

Figure 30: Insomnia Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 52

Figure 31: Insomnia Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 53

Figure 32: Insomnia Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017 54

Figure 33: Insomnia Therapeutics Market, Global, Diseased Population (millions), 2002-2017 56

Figure 34: Insomnia Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017 57

Figure 35: Insomnia Therapeutics Market, Global, Diagnosis Population (millions), 2002-2017 58

Figure 36: Insomnia Therapeutics Market, Global, Prescription Population (millions), 2002-2017 59

Figure 37: Insomnia Therapeutics Market, Global, Market Drivers and Barriers, 2010-2017 60

Figure 38: Restless Leg Syndrome Therapeutics Market, Global, Revenue Forecasts ($bn), 2002-2017 62

Figure 39: Restless Leg Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 63

Figure 40: Restless Leg Syndrome Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017 64

Figure 41: Restless Leg Syndrome Therapeutics Market, Global, Diseased Population (millions), 2002-2017 66

Figure 42: Restless Leg Syndrome Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017 67

Figure 43: Restless Leg Syndrome Therapeutics Market, Global, Diagnosis Population (millions), 2002-2017 68

Figure 44: Restless Leg Syndrome Therapeutics Market, Global, Prescription Population (millions), 2002-2017 69

Figure 45: Restless Leg Syndrome, Therapeutics Market, Drivers and Barriers, 2010-2017 70

Figure 46: Narcolepsy Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 72

Figure 47: Narcolepsy Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 73

Figure 48: Narcolepsy Therapeutics Market, Global, Treatment Usage Patterns (thousands), 2002-2017 74

Figure 49: Narcolepsy Therapeutics Market, Global, Diseased Population (thousands), 2002-2017 76

Figure 50: Narcolepsy Therapeutics Market, Global, Treatment Seeking Population (thousands), 2002-2017 77

Figure 51: Narcolepsy Therapeutics Market, Global, Diagnosis Population (thousands), 2002-2017 78

Figure 52: Narcolepsy Therapeutics Market, Global, Prescription Population (thousands), 2002-2017 79

Figure 53: Narcolepsy Therapeutics Market, Global, Drivers and Barriers, 2010-2017 80

Figure 54: Sleep Apnea Therapeutics Market, Global, Revenue Forecasts ($m), 2002-2017 82

Figure 55: Sleep Apnea Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 83

Figure 56: Sleep Apnea Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2017 84

Figure 57: Sleep Apnea Therapeutics Market, Global, Diseased Population (millions), 2002-2017 86

Figure 58: Sleep Apnea Therapeutics Market, Global, Treatment Seeking Population (millions), 2002-2017 87

Figure 59: Sleep Apnea Therapeutics Market, Global, Diagnosed Population (millions), 2002-2017 88

Figure 60: Sleep Apnea Therapeutics Market, Global, Prescription Population (millions), 2002-2017 89

Figure 61: Sleep Apnea Therapeutics, Market Drivers and Barriers, 2010-2017 90

Figure 62: Sleep Disorders Market, Global, R&D Pipeline by Indications (%), 2010 92

Figure 63: Sleep Disorders Market, Global, R&D Pipeline by Phase (%), 2010 93

Figure 64: Insomnia Therapeutics Market, Global, Pipeline by Phase and Class, 2010 94

Figure 65: Restless Leg Syndrome Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 98

Figure 66: Narcolepsy Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 100

Figure 67: Sleep Apnea Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010 102

Figure 68: SWOT Analysis of Sanofi-Aventis 106

Figure 69: SWOT Analysis of King Pharmaceuticals, Inc. 107

Figure 70: SWOT Analysis of Questcor Pharmaceuticals 108

Figure 71: SWOT Analysis of Novartis 110

Figure 72: SWOT Analysis of GlaxoSmithKline 112

Figure 73: SWOT Analysis of Pfizer 114

Figure 74: SWOT Analysis of Boehringer Ingelheim GmbH 118

Figure 75: SWOT Analysis of Cephalon Pharmaceuticals 120

Figure 76: SWOT Analysis of Schwarz Pharma 124

Figure 77: SWOT Analysis of Mylan Pharma 126

Figure 78: Sleep Disorders Market, Global, Deals by Type, 2004-2010 127

Figure 79: Sleep Disorders Market, Global, Major Deals By Year, 2008-2010 128

Figure 80: Sleep Disorder Market, Global, Major Deals By Geography, 2004-2010 134

Figure 81: Sleep Disorder Market, Global, Co-Development Strategies By Geography, 2004-2010 135

Figure 82: GBI Research Market Forecasting Model 139

Companies mentioned

Sanofi-Aventis

King Pharmaceuticals, Inc.

Questcor Pharmaceuticals, Inc.

Novartis

GlaxoSmithKline plc

Pfizer

Boehringer Ingelheim

Cephalon Pharmaceuticals

Schwarz Pharma

Mylan Pharma

To order this report:

Sleep Disorders Market to 2017 - Generic Substitution Coupled With a Weak Pipeline Will Negatively Impact the Market

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:  
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: +1-805-652-2626
Intl: +1-805-652-2626

SOURCE Reportlinker

PRN Top Stories Newsletters

Sign up to get PRN’s top stories and curated news delivered to your inbox weekly!

Thank you for subscribing!

By signing up you agree to receive content from us.
Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our PRN Consumer Newsletter Privacy Notice. You can withdraw your consent at any time in the footer of every email you'll receive. Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten.
Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer PRN Consumer Newsletter Privacy Notice. Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen. En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part.
Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant PRN Consumer Newsletter Privacy Notice. Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu. Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на PRN. Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.